U.S. pharma giant copyright scrapped two experimental weight loss capsules very last year—a when-each day tablet, lotiglipron, resulting from elevated liver enzymes in addition to a two times-daily capsule, danuglipron, because of robust Unwanted effects—but CEO Albert Bourla has explained the company is decided to “play and earn” during th